File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Preliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally-advanced nasopharyngeal carcinoma: NPC-9901 trial by the Hong Kong Nasopharyngeal Cancer Study Group

TitlePreliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally-advanced nasopharyngeal carcinoma: NPC-9901 trial by the Hong Kong Nasopharyngeal Cancer Study Group
Authors
Issue Date2005
Citation
Journal of Clinical Oncology, 2005, v. 23, n. 28, p. 6966-6975 How to Cite?
AbstractPurpose: This randomized study compared the results achieved by concurrent chemoradiotherapy (CRT) versus radiotherapy (RT) alone for nasopharyngeal carcinoma (NPC) with advanced nodal disease. Patients and Methods: Patients with nonkeratinizing/undifferentiated NPC staged T1-4N2-3M0 were randomized to CRT or RT. Both arms were treated with the same RT technique and dose fractionation. The CRT patients were given cisplatin 100 mg/m2 on days 1, 22, and 43, followed by cisplatin 80 mg/m2 and fluorouracil 1,000 mg/m 2/d for 96 hours starting on days 71, 99, and 127. Results: From 1999 to January 2004, 348 eligible patients were randomly assigned; the median follow-up was 2.3 years. The two arms were well-balanced in all prognostic factors and RT parameters. The CRT arm achieved significantly higher failure-free survival (72% v 62% at 3-year, P = .027), mostly as a result of an improvement in locoregional control (92% v 82%, P = .005). However, distant control did not improve significantly (76% v 73%, P = .47), and the overall survival rates were almost identical (78% v 78%, P = .97). In addition, the CRT arm had significantly more acute toxicities (84% v 53%, P < .001) and late toxicities (28% v 13% at 3-year, P = .024). Conclusion: Preliminary results confirmed that CRT could significantly improve tumor control, particularly at locoregional sites. However, there was significant increase in the risk of toxicities and no early gain in overall survival. Longer follow-up is needed to confirm the ultimate therapeutic ratio. © 2005 by American Society of Clinical Oncology.
Persistent Identifierhttp://hdl.handle.net/10722/213897
ISSN
2015 Impact Factor: 20.982
2015 SCImago Journal Rankings: 9.204

 

DC FieldValueLanguage
dc.contributor.authorLee, Anne W M-
dc.contributor.authorLau, W. H.-
dc.contributor.authorTung, Stewart Y.-
dc.contributor.authorChua, Daniel T T-
dc.contributor.authorChappell, Rick-
dc.contributor.authorXu, L.-
dc.contributor.authorSiu, Lillian-
dc.contributor.authorSze, W. M.-
dc.contributor.authorLeung, T. W.-
dc.contributor.authorSham, Jonathan S T-
dc.contributor.authorNgan, Roger K C-
dc.contributor.authorLaw, Stephen C K-
dc.contributor.authorYau, T. K.-
dc.contributor.authorAu, Joseph S K-
dc.contributor.authorO'Sullivan, Brian-
dc.contributor.authorPang, Ellie S Y-
dc.contributor.authorO, S. K.-
dc.contributor.authorAu, Gordon K H-
dc.contributor.authorLau, Joseph T.-
dc.date.accessioned2015-08-19T13:41:08Z-
dc.date.available2015-08-19T13:41:08Z-
dc.date.issued2005-
dc.identifier.citationJournal of Clinical Oncology, 2005, v. 23, n. 28, p. 6966-6975-
dc.identifier.issn0732-183X-
dc.identifier.urihttp://hdl.handle.net/10722/213897-
dc.description.abstractPurpose: This randomized study compared the results achieved by concurrent chemoradiotherapy (CRT) versus radiotherapy (RT) alone for nasopharyngeal carcinoma (NPC) with advanced nodal disease. Patients and Methods: Patients with nonkeratinizing/undifferentiated NPC staged T1-4N2-3M0 were randomized to CRT or RT. Both arms were treated with the same RT technique and dose fractionation. The CRT patients were given cisplatin 100 mg/m2 on days 1, 22, and 43, followed by cisplatin 80 mg/m2 and fluorouracil 1,000 mg/m 2/d for 96 hours starting on days 71, 99, and 127. Results: From 1999 to January 2004, 348 eligible patients were randomly assigned; the median follow-up was 2.3 years. The two arms were well-balanced in all prognostic factors and RT parameters. The CRT arm achieved significantly higher failure-free survival (72% v 62% at 3-year, P = .027), mostly as a result of an improvement in locoregional control (92% v 82%, P = .005). However, distant control did not improve significantly (76% v 73%, P = .47), and the overall survival rates were almost identical (78% v 78%, P = .97). In addition, the CRT arm had significantly more acute toxicities (84% v 53%, P < .001) and late toxicities (28% v 13% at 3-year, P = .024). Conclusion: Preliminary results confirmed that CRT could significantly improve tumor control, particularly at locoregional sites. However, there was significant increase in the risk of toxicities and no early gain in overall survival. Longer follow-up is needed to confirm the ultimate therapeutic ratio. © 2005 by American Society of Clinical Oncology.-
dc.languageeng-
dc.relation.ispartofJournal of Clinical Oncology-
dc.titlePreliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally-advanced nasopharyngeal carcinoma: NPC-9901 trial by the Hong Kong Nasopharyngeal Cancer Study Group-
dc.typeArticle-
dc.description.natureLink_to_subscribed_fulltext-
dc.identifier.doi10.1200/JCO.2004.00.7542-
dc.identifier.pmid16192584-
dc.identifier.scopuseid_2-s2.0-27344447760-
dc.identifier.hkuros131362-
dc.identifier.hkuros124599-
dc.identifier.volume23-
dc.identifier.issue28-
dc.identifier.spage6966-
dc.identifier.epage6975-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats